{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:08:59Z","timestamp":1793380139976,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The role of ursodeoxycholic acid (UDCA) in the prevention of hepatic complications after allogeneic stem cell transplantation was studied in a prospective randomized open-label multicenter trial. A total of 242 patients were allocated to receive (n\u2009=\u2009123) or not to receive (n\u2009=\u2009119) UDCA in the dose of 12 mg\/kg\/d orally from the day preceding the conditioning until day 90 after transplantation. In the UDCA-treated group a significantly smaller proportion of patients developed a serum bilirubin level exceeding 50 \u03bcM (18 of 123 versus 31 of 119, P\u2009=\u2009.04), and similarly a smaller proportion of patients exceeded the alanine aminotransferase level of 100 U\/L. There was no difference in the incidence of veno-occlusive disease of the liver. Compared to the control group, in the UDCA-treated group there was a nonsignificant trend toward a lower overall incidence of acute graft-versus-host disease (GVHD) and a significantly lower incidence of grade III to IV acute GVHD (5 of 123 versus 17 of 119,P\u2009=\u2009.01), stage II to IV liver and intestinal GVHD, and stage III to IV skin GVHD. There was no difference in the incidence of chronic GVHD or in the relapse rate. Among the patients given UDCA, the survival at 1 year was significantly better, 71% versus 55% (P\u2009=\u2009.02), and the nonrelapse mortality rate was lower, 19% versus 34% (P\u2009=\u2009.01), than in the control group. There were significantly more deaths in GVHD in the control group. In conclusion, UDCA administration reduced hepatic problems and severe acute GVHD and improved survival. These results suggest a role for UDCA in the prevention of transplant-related complications in allogeneic transplantation.<\/jats:p>","DOI":"10.1182\/blood-2001-12-0159","type":"journal-article","created":{"date-parts":[[2002,8,28]],"date-time":"2002-08-28T14:22:57Z","timestamp":1030544577000},"page":"1977-1983","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":225,"title":["Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation"],"prefix":"10.1182","volume":"100","author":[{"given":"Tapani","family":"Ruutu","sequence":"first","affiliation":[{"name":"From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, and Department of Medicine, Huddinge University Hospital, Huddinge, Sweden; and Department of Medicine, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Eriksson","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, and Department of Medicine, Huddinge University Hospital, Huddinge, Sweden; and Department of Medicine, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Remes","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, and Department of Medicine, Huddinge University Hospital, Huddinge, Sweden; and Department of Medicine, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeva","family":"Juvonen","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, and Department of Medicine, Huddinge University Hospital, Huddinge, Sweden; and Department of Medicine, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"Volin","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, and Department of Medicine, Huddinge University Hospital, Huddinge, Sweden; and Department of Medicine, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Remberger","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, and Department of Medicine, Huddinge University Hospital, Huddinge, Sweden; and Department of Medicine, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terttu","family":"Parkkali","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, and Department of Medicine, Huddinge University Hospital, Huddinge, Sweden; and Department of Medicine, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Ha\u0308gglund","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, and Department of Medicine, Huddinge University Hospital, Huddinge, Sweden; and Department of Medicine, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Ringde\u0301n","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, and Department of Medicine, Huddinge University Hospital, Huddinge, Sweden; and Department of Medicine, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111616334834200_B1","first-page":"737","article-title":"Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high risk population.","volume":"92","author":"Richardson","year":"1998","journal-title":"Blood."},{"key":"2019111616334834200_B2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol."},{"key":"2019111616334834200_B3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9343(00)00318-1","article-title":"Ursodeoxycholic acid therapy in hepatobiliary disease.","volume":"108","author":"Kowdley","year":"2000","journal-title":"Am J Med."},{"key":"2019111616334834200_B4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.1840100404","article-title":"Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.","volume":"10","author":"Batta","year":"1989","journal-title":"Hepatology."},{"key":"2019111616334834200_B5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/gut.30.8.1110","article-title":"Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment.","volume":"30","author":"Chretien","year":"1989","journal-title":"Gut."},{"key":"2019111616334834200_B6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/978-94-011-4884-9_17","article-title":"Ursodeoxycholic acid treatment of primary biliary cirrhosis: potential mechanisms of action.","volume-title":"Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment.","author":"Paumgartner","year":"1998"},{"key":"2019111616334834200_B7","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/0016-5085(93)90653-T","article-title":"Molecular aspects of membrane stabilization by ursodeoxycholate.","volume":"104","author":"Gu\u0308ldu\u0308tuna","year":"1993","journal-title":"Gastroenterology."},{"key":"2019111616334834200_B8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0016-5085(98)70377-4","article-title":"Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells.","volume":"115","author":"Neuman","year":"1998","journal-title":"Gastroenterology."},{"key":"2019111616334834200_B9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.1840160213","article-title":"Immunomodulatory effects of ursodeoxycholic acid on immune responses.","volume":"16","author":"Yoshikawa","year":"1992","journal-title":"Hepatology."},{"key":"2019111616334834200_B10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/hep.510280601","article-title":"Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications.","volume":"28","author":"Beuers","year":"1998","journal-title":"Hepatology."},{"key":"2019111616334834200_B11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet."},{"key":"2019111616334834200_B12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0168-8278(00)80232-9","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past\u2014issues for the future.","volume":"32","author":"Poupon","year":"2000","journal-title":"J Hepatol."},{"key":"2019111616334834200_B13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/hep.510260408","article-title":"A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection.","volume":"26","author":"Barnes","year":"1997","journal-title":"Hepatology."},{"key":"2019111616334834200_B14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation: a randomized, double-blind, placebo-controlled trial.","volume":"128","author":"Essell","year":"1998","journal-title":"Ann Intern Med."},{"key":"2019111616334834200_B15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","article-title":"The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation.","volume":"64","author":"Ohashi","year":"2000","journal-title":"Am J Hematol."},{"key":"2019111616334834200_B16","doi-asserted-by":"crossref","first-page":"624","DOI":"10.7326\/0003-4819-116-8-624","article-title":"Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver.","volume":"116","author":"Fried","year":"1992","journal-title":"Ann Intern Med."},{"key":"2019111616334834200_B17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1365-2141.1997.d01-2085.x","article-title":"Hepatic GVHD after HLA-haploidentical bone marrow transplantation in children with severe combined immunodeficiency: the effect of ursodeoxycholic acid.","volume":"96","author":"Wulffraat","year":"1997","journal-title":"Br J Haematol."},{"key":"2019111616334834200_B18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology."},{"key":"2019111616334834200_B19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Veno-occlusive disease of the liver following bone marrow transplantation.","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation."},{"key":"2019111616334834200_B20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation."},{"key":"2019111616334834200_B21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone marrow transplantation.","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med."},{"key":"2019111616334834200_B22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients.","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med."},{"key":"2019111616334834200_B23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.bloodjournal572267","article-title":"Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.","volume":"57","author":"Sullivan","year":"1981","journal-title":"Blood."},{"key":"2019111616334834200_B24","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood.V96.7.2391","article-title":"Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.","volume":"96","author":"Ruutu","year":"2000","journal-title":"Blood."},{"key":"2019111616334834200_B25","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation.","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood."},{"key":"2019111616334834200_B26","first-page":"75","article-title":"Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.","volume":"17","author":"Rozman","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"2019111616334834200_B27","first-page":"3599","article-title":"Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation.","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood."},{"key":"2019111616334834200_B28","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","article-title":"A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with hematological malignancies: a report from the Nordic Bone Marrow Transplantation Group.","volume":"83","author":"Ringde\u0301n","year":"1994","journal-title":"Blood."},{"key":"2019111616334834200_B29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.1840110104","article-title":"Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid.","volume":"11","author":"Calmus","year":"1990","journal-title":"Hepatology."},{"key":"2019111616334834200_B30","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial.","volume":"30","author":"Angulo","year":"1999","journal-title":"J Hepatol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/6\/1977\/1255646\/h81802001977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/6\/1977\/1255646\/h81802001977.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T16:34:01Z","timestamp":1573922041000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/6\/1977\/16524\/Ursodeoxycholic-acid-for-the-prevention-of-hepatic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9,15]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,9,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2001-12-0159","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,9,15]]}}}